Valuation: Profound Medical Corp

Market Cap 306M 220M 191M 180M 163M 21.04B 309M 2.15B 826M 10.71B 827M 809M 33.98B P/E 2026 *
-6.7x
P/E 2027 * -9.83x
Enterprise Value 306M 220M 191M 180M 163M 21.04B 309M 2.15B 826M 10.71B 827M 809M 33.98B EV / Sales 2026 *
8.45x
EV / Sales 2027 * 5.15x
Free-Float
95.94%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 59 01/09/2026
Director of Finance/CFO - 14/08/2026
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-0.03%+27.98%+20.11% 225B
+1.55%-2.12%+6.95%-19.49% 141B
+2.38%+3.07%-15.95%+24.86% 130B
+4.82%-5.75%-56.14%-15.32% 62.29B
+1.99%-0.03%-18.12%-12.87% 49.39B
+1.36%-4.87%+10.25%+16.88% 48.63B
-0.09%-2.69%+19.12%+29.42% 41.42B
+0.41%+0.15%+38.80%+53.43% 40.12B
+2.16%-2.35%-17.45%+52.38% 31.23B
Average +1.69%-3.23%-0.51%+16.60% 85.52B
Weighted average by Cap. +1.58%-2.40%+4.05%+12.03%

Financials

2026 *2027 *
Net sales 36.22M 26.04M 22.56M 21.28M 19.31M 2.49B 36.51M 254M 97.68M 1.27B 97.84M 95.72M 4.02B 59.46M 42.74M 37.04M 34.93M 31.7M 4.09B 59.94M 417M 160M 2.08B 161M 157M 6.6B
Net income -44.08M -31.69M -27.46M -25.9M -23.5M -3.03B -44.43M -309M -119M -1.54B -119M -116M -4.89B -31.27M -22.48M -19.48M -18.37M -16.67M -2.15B -31.52M -219M -84.32M -1.09B -84.47M -82.63M -3.47B
Net Debt - -
Logo Profound Medical Corp
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!